ABVC Biopharma, Inc. — Form 10-Q Summary
Filing identity: The supplied filing names the registrant as American BriVision (Holding) Corporation, not ABVC Biopharma, Inc. This summary follows the filing’s reported figures and disclosures. The unaudited reporting period ended September 30, 2019; comparisons are with the three and nine months ended September 30, 2018, and balance-sheet comparisons are with December 31, 2018.
Business context
The company describes itself as a clinical-stage biotechnology and medical-device developer, with drug-development and vitreous-substitute programs, alongside BioKey’s contract development and manufacturing (CDMO) business. Its drug and device programs had not generated substantial revenue; 2019 revenue was primarily from CDMO services. The February 2019 acquisitions of BioLite and BioKey and a May 2019 1-for-18 reverse stock split materially affect comparability and share-count interpretation.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $197,733 | $747 | $601,757 | $3,976 |
| Gross profit | $194,936 | $210 | $584,109 | $1,120 |
| Operating expenses | $1,310,558 | $396,495 | $2,919,104 | $1,596,036 |
| Operating loss | $(1,115,622) | $(396,285) | $(2,334,995) | $(1,594,916) |
| Net loss | $(1,329,685) | $(687,300) | $(2,817,454) | $(2,136,962) |
| Net loss per share, basic and diluted | $(0.07) | $(0.06) | $(0.16) | $(0.18) |
Gross margin was approximately 98.6% in Q3 and 97.1% for the nine-month period, reflecting very low reported cost of revenue. Management attributed revenue growth mainly to CDMO. Nine-month SG&A rose to $2.12 million from $1.21 million, mainly due to professional fees; R&D increased to $779,000 from $359,000, which management attributed primarily to pipeline progress and related milestone payments. Nine-month interest expense was $375,000 versus $346,000. The filing reports a $183,000 equity-investment loss for the period.
At September 30, 2019, cash and cash equivalents were $1.04 million, with restricted cash of $16,122. Current assets were $1.71 million and current liabilities $5.88 million, producing a $4.17 million working-capital deficit. Total assets were $7.40 million and total liabilities $6.67 million; total equity was $730,000, compared with a $5.34 million deficit at year-end 2018. The balance sheet included $1.89 million in short-term bank loans, $22,547 current portion of long-term bank loans, and $1.76 million in convertible notes. Operating lease liabilities totaled $375,016.
For the nine months, operating cash outflow was $1.64 million, investing cash outflow was $35,079, and financing cash inflow was $2.48 million. Cash, cash equivalents and restricted cash increased by $809,019 to $1.05 million. Financing included $1.0 million of bank borrowing and $957,500 of convertible-note proceeds.
Material changes, outlook and risks
- Revenue remained small relative to operating costs, while nine-month net loss increased 32% year over year. Q3 net loss was nearly twice the prior-year quarter.
- Related-party debt conversions reduced amounts due to related parties substantially: the balance fell from $7.75 million at year-end 2018 to $376,460. The filing describes debt-to-equity conversions and substantial share issuance; common shares outstanding were 19,478,168 as of November 15, 2019.
- New 2019 convertible notes included 20% annual interest and conversion provisions generally tied to a $0.50 fixed price or a discount to a qualifying offering. Existing notes included maturities beginning in November 2019. The Cathay Bank line had a January 1, 2020 maturity and security interests in substantially all assets of the company and BriVision, as described in the filing.
- Management stated that substantial additional capital is needed and that continuation as a going concern depends on profitable operations and/or obtaining financing. It identified equity sales, borrowing, and related-party financing as plans, but gave no assurance these would succeed. The filing reports accumulated deficit of $14.77 million and a nine-month loss of $2.82 million.
- No quantified revenue, earnings, cash-flow, or financing guidance is provided. The filing discusses clinical-stage programs and reports that a November 2019 study report for ABV-1504 showed tolerability and a greater week-six HAM-D-17 reduction in the high-dose group than placebo; management planned discussions with regulators about a possible Phase III path. It also refers to encouraging first-in-human Vitargus results announced in October 2019. These are developments disclosed after the quarter, not Q3 financial results.
- Management concluded disclosure controls and procedures were not effective as of September 30, 2019. No legal proceedings were reported. The filing cautions that forward-looking statements are subject to significant uncertainties, including competition, market conditions, financing availability and penny-stock-related trading risks.
Important facts for investors to verify
- Confirm the registrant and issuer identity: the supplied 10-Q is filed under American BriVision (Holding) Corporation.
- Review financing runway, near-term maturities, borrowing terms, collateral, and whether the company can secure additional capital.
- Assess potential dilution from convertible notes, debt conversions, and other equity issuances; account for the reverse split when comparing share data.
- Validate the source, sustainability, and margins of CDMO revenue and the timing and funding needs of clinical programs.
- Review the basis for the going-concern assessment, the ineffective disclosure-controls conclusion, and the recoverability of deferred tax assets and investments.